Skip to main content
Takeda unveils details on 12 new molecular entities worth billions

In a recent update, Takeda touted its plans for a dozen new molecular entities that could potentially generate 14 approvals and over $10 billion in potential sales. The NMEs are part of a first wave that will target cancer, gastroenterology, neuroscience, rare diseases and vaccines, and will be followed by another wave of treatments using new platforms, such as cell and gene therapies, as well as novel mechanisms.

Full Story: